Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Vixarelimab by Genentech USA for Ulcerative Colitis: Likelihood of Approval
Vixarelimab is under clinical development by Genentech USA and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's Vixarelimab?
Vixarelimab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris). According...